Recent approvals of RNAi-based medications have rekindled interest in the industry, possibly strengthening the power of the therapeutic platform. Many groundbreaking research endeavors have offered new carrier architectures for carrying nucleic acid payloads. Because nucleic acids are charged negatively, utilizing complementary positively charged compounds sounds like a smart approach. The presence of such a cationic charge in the delivery vector, however, is a serious problem, increasing cytotoxicity. Charge-alteration-based approaches can address the evolving needs of nucleic acid-based therapies. Medication delivery platforms have become significantly smarter and safer.The research focuses on exciting recent advancements in management-switching technology. This study summarizes some of these fascinating possibilities, written by authors with special attention to the underlying physics of charge conversion processes. Charge reversal techniques are fairly new and are still in the early development phases. Translating such ideas would require significant investigation, including studies of safety, efficacy, and immunogenicity using relevant disease models.
Prioritizing Digitalization Use Cases during Early Development Phases of Large Scale Manufacturing Systems
